Ayala Pharmaceuticals, Inc. (ADXS)
OTCMKTS · Delayed Price · Currency is USD
0.6036
0.00 (0.00%)
Inactive · Last trade price on Feb 3, 2026
Ayala Pharmaceuticals Company Description
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States.
The company is developing AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
The company was incorporated in 1987 and is based in Monmouth Junction, New Jersey.
Ayala Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Kenneth Berlin |
Contact Details
Address: 9 Deer Park Drive Monmouth Junction, New Jersey 08852 United States | |
| Phone | 609 452 9813 |
| Website | ayalapharma.com |
Stock Details
| Ticker Symbol | ADXS |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US0076244062 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kenneth A. Berlin J.D. | Chief Executive Officer, President and Director |
| Irit Klipper-Avni M.A. | Vice President of Human Resources |
| Dana Gelbaum M.B.A., M.Sc. | GM and Chief Business Officer |